Viking Therapeutics raises ~$548M via stock and 2.00% convertible notes offerings

Viking Therapeutics, Inc.

Equity offering: 7,857,143 shares sold at $35.00/share, plus full exercise of the 1,178,571-share underwriter option; net proceeds ~$297.0M; closed Sept. 25, 2026.
Debt offering: $225M of 2.00% convertible senior notes due Oct. 15, 2032, plus $33.75M option exercised in full; net proceeds ~$250.8M; interest payable semi-annually from April 15, 2027.
Notes convert initially at ~$50.75/share (19.7044 shares per $1,000), a 45% premium to the $35.00 equity offering price; U.S. Bank Trust Company is trustee.
Proceeds earmarked for clinical development and commercialization of VK2735, development of VK3019, and general R&D, working capital and corporate purposes.
Notes callable on or after Oct. 22, 2029 if the stock exceeds 130% of the conversion price; cleanup redemption permitted if less than 15% of principal remains outstanding.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.